c-erbB-3 protein expression in ductal carcinoma in situ of the breast.

[1]  I. Ellis,et al.  C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. , 1996, British Journal of Cancer.

[2]  W. Hiddemann,et al.  Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[4]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[5]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[6]  C. Quinn,et al.  c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survival , 1994, Histopathology.

[7]  W. Gregory,et al.  The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.

[8]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[9]  D. Barnes,et al.  Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.

[10]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[11]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[12]  R. Kumar,et al.  Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells , 1991, Molecular and cellular biology.

[13]  J. Bártková,et al.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.

[14]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[15]  S. Ashley,et al.  Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.

[16]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[18]  I. Damjanov,et al.  Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[19]  E. Karaöz,et al.  Immunohistochemical localization of the epidermal growth factor receptor in normal mouse tissues. , 1997, Acta physiologica Hungarica.

[20]  W. Gullick,et al.  Prevalence of C-erbb3 expression in squamous-cell carcinomas of the cervix as determined by the monoclonal-antibody rtj2. , 1995, International journal of oncology.

[21]  N. Lemoine,et al.  c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. , 1994, European journal of cancer.

[22]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.